Found 2 results
Filters: Author is T. Isbir  [Clear All Filters]
K. K. Ol, Agachan, B., Gormus, U., Toptas, B., and Isbir, T., Cox-2 gene polymorphism and IL-6 levels in coronary artery disease, vol. 10, pp. 810-816, 2011.
Antman EM, DeMets D and Loscalzo J (2005). Cyclooxygenase inhibition and cardiovascular risk. Circulation 112: 759-770. doi:10.1161/CIRCULATIONAHA.105.568451 PMid:16061757 Barrett-Connor EL, Cohn BA, Wingard DL and Edelstein SL (1991). Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 265: 627-631. doi:10.1001/jama.265.5.627 Belton O, Byrne D, Kearney D, Leahy A, et al. (2000). Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102: 840-845. PMid:10952950 Biondi-Zoccai GG, Abbate A, Liuzzo G and Biasucci LM (2003). Atherothrombosis, inflammation, and diabetes. J. Am. Coll. Cardiol. 41: 1071-1077. doi:10.1016/S0735-1097(03)00088-3 Cipollone F, Prontera C, Pini B, Marini M, et al. (2001). Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104: 921-927. doi:10.1161/hc3401.093152 PMid:11514380 Cipollone F, Fazia M, Iezzi A, Zucchelli M, et al. (2003). Suppression of the functionally coupled cyclooxygenase-2/ prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107: 1479-1485. doi:10.1161/01.CIR.0000056530.03783.81 PMid:12654603 Davis SN, Granner DK, Hardman JG and Limbird LE (2006). Insulin, Oral Hypoglycemic Agents and Pharmacology of Endocrin Pancreas - Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 11th edn. The McGraw-Hill Companies Inc., New York. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, et al. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5: 698-701. doi:10.1038/9550 PMid:10371510 Hegener HH, Diehl KA, Kurth T, Gaziano JM, et al. (2006). Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J. Thromb. Haemost. 4: 1718-1722. doi:10.1111/j.1538-7836.2006.02054.x PMid:16879213 Huuskonen KH, Kunnas TA, Tanner MM, Mikkelsson J, et al. (2008). COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm. 2008: 289453. doi:10.1155/2008/289453 PMid:18385811    PMCid:2276816 Kohsaka S, Volcik KA, Folsom AR, Wu KK, et al. (2008). Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196: 926-930. doi:10.1016/j.atherosclerosis.2007.02.010 PMid:17350020 Kosaka T, Miyata A, Ihara H, Hara S, et al. (1994). Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem. 221: 889-897. doi:10.1111/j.1432-1033.1994.tb18804.x PMid:8181472 Laakso M, Voutilainen E, Sarlund H, Aro A, et al. (1985). Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis 56: 271-281. doi:10.1016/0021-9150(85)90003-6 Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215. doi:10.1093/nar/16.3.1215 PMid:3344216    PMCid:334765 Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, et al. (2006). Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin. Chim. Acta 368: 138-143. doi:10.1016/j.cca.2005.12.019 PMid:16458279 Papafili A, Hill MR, Brull DJ, McAnulty RJ, et al. (2002). Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 22: 1631-1636. doi:10.1161/01.ATV.0000030340.80207.C5 PMid:12377741 Paramo JA, Rodriguez JA, Beloqui O and Orbe J (2005). Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis? Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 303-311. doi:10.2174/1568006054553381 Pisetsky DS and St. Clair EW (2001). Progress in the treatment of rheumatoid arthritis. JAMA 286: 2787-2790. doi:10.1001/jama.286.22.2787 Prescott SM and Fitzpatrick FA (2000). Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta 1470: M69-M78. PMid:10722929 Rudock ME, Liu Y, Ziegler JT, Allen SG, et al. (2009). Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the diabetes heart study. Atherosclerosis 203: 459-465. doi:10.1016/j.atherosclerosis.2008.07.018 PMid:18768181    PMCid:2699582 Schonbeck U, Sukhova GK, Graber P, Coulter S, et al. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155: 1281-1291. doi:10.1016/S0002-9440(10)65230-3 Sjöholm A and Nyström T (2005). Endothelial inflammation in insulin resistance. Lancet 365: 610-612. PMid:15708106 World Health Organization (WHO) (1999). Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications - Report of a WHO (World Health Organization) Consultation. World Health Organization, Geneva. Yokoyama C and Tanabe T (1989). Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun. 165: 888-894. doi:10.1016/S0006-291X(89)80049-X
K. F. Narter, Agachan, B., Sozen, S., Cincin, Z. B., and Isbir, T., CCR2-64I is a risk factor for development of bladder cancer, vol. 9, pp. 685-692, 2010.
Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, et al. (2002). Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J. Am. Soc. Nephrol. 13: 754-758. PMid:11856781   Amann B, Perabo FG, Wirger A, Hugenschmidt H, et al. (1998). Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br. J. Urol. 82: 118-121. PMid:9698673   Balkwill F (2004). Cancer and the chemokine network. Nat. Rev. Cancer 4: 540-550. PMid:15229479   Barrett JC, Fry B, Maller J and Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265. PMid:15297300   Coelho A, Matos A, Catarino R, Pinto D, et al. (2005). Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol. Oncol. 96: 760-764. PMid:15721423   Dawson SJ, Morris PJ and Latchman DS (1996). A single amino acid change converts an inhibitory transcription factor into an activator. J. Biol. Chem. 271: 11631-11633. PMid:8662774   Ginestier C, Liu S, Diebel ME, Korkaya H, et al. (2010). CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest 120: 485-497. PMid:20051626 PMCid:2810075   Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, et al. (2001). Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann. Intern. Med. 135: 782-795. PMid:11694103   Jensen OM, Esteve J, Moller H and Renard H (1990). Cancer in the European Community and its member states. Eur. J. Cancer 26: 1167-1256.   Kantor AF, Hartge P, Hoover RN, Narayana AS, et al. (1984). Urinary tract infection and risk of bladder cancer. Am. J. Epidemiol. 119: 510-515. PMid:6711540   Karnoub AE and Weinberg RA (2006). Chemokine networks and breast cancer metastasis. Breast Dis. 26: 75-85. PMid:17473367   Kaufman DS, Shipley WU and Feldman AS (2009). Bladder cancer. Lancet 374: 239-249.   Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, et al. (1998). A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. 4: 350-353. PMid:9500612   Luster AD (1998). Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338: 436-445. PMid:9459648   Mackay CR (1997). Chemokines: what chemokine is that? Curr. Biol. 7: R384-R386.   Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215. PMid:3344216 PMCid:334765   Miyagishi R, Niino M, Fukazawa T, Yabe I, et al. (2003). C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J. Neuroimmunol. 145: 135-138. PMid:14644039   Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, et al. (2003). Effects of CCR5-Delta32 and CCR2-64I alleles on HIV- 1 disease progression: the protection varies with duration of infection. AIDS 17: 377-387. PMid:12556692   Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, et al. (2004). A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 18: 729-738. PMid:15075507   Navratilova Z (2006). Polymorphisms in CCL2 & CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 150: 191-204. PMid:17426779   Rollins BJ (1997). Chemokines. Blood 90: 909-928. PMid:9242519   Rossi D and Zlotnik A (2000). The biology of chemokines and their receptors. Annu. Rev. Immunol. 18: 217-242. PMid:10837058   Rovin BH, Lu L and Saxena R (1999). A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem. Biophys. Res. Commun. 259: 344-348. PMid:10362511   Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, et al. (2010). The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 105: 300-308. PMid:19912200   Smith MW, Carrington M, Winkler C, Lomb D, et al. (1997). CCR2 chemokine receptor and AIDS progression. Nat. Med. 3: 1052-1053. PMid:9334699   Struyf S, Proost P and Van Damme J (2003). Regulation of the immune response by the interaction of chemokines and proteases. Adv. Immunol. 81: 1-44.   Szalai C, Duba J, Prohaszka Z, Kalina A, et al. (2001). Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 158: 233-239.   Vandercappellen J, Van Damme J and Struyf S (2008). The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267: 226-244. PMid:18579287   Vázquez-Lavista LG, Lima G, Gabilondo F and Llorente L (2009). Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology 74: 414-418. PMid:19646633   Vicari AP and Caux C (2002). Chemokines in cancer. Cytokine Growth Factor Rev. 13: 143-154.   Yoshie O, Imai T and Nomiyama H (2001). Chemokines in immunity. Adv. Immunol. 78: 57-110.   Zafiropoulos A, Crikas N, Passam AM and Spandidos DA (2004). Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J. Med. Genet. 41: e59. PMid:15121787 PMCid:1735773